AIMS Bioengineering, 2016, 3(4): 552-565. doi: 10.3934/bioeng.2016.4.552

Research article

Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

Development and validation of a skin fibroblast biomarker profile for schizophrenic patients

1 Neuropsychiatric Research Laboratory, Faculty of Medicine and Health, School of Health and Medical Sciences, Örebro University, Örebro, Sweden
2 Metabolic Engineering and Bioinformatics Group, Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece
3 e-NIOS Applications PC, Athens, Greece
4 Laboratory of Biotechnology, School of Chemical Engineering, National Technical University of Athens, Athens, Greece

Gene expression profiles of non-neural tissues through microarray technology could be used in schizophrenia studies, adding more information to the results from similar studies on postmortem brain tissue. The ultimate goal of such studies is to develop accessible biomarkers. Supervised machine learning methodologies were used, in order to examine if the gene expression from skin fibroblast cells could be exploited for the classification of schizophrenic subjects. A dataset of skin fibroblasts gene expression of schizophrenia patients was obtained from Gene Expression Omnibus database. After applying statistical criteria, we concluded to genes that present a differential expression between the schizophrenic patients and the healthy controls. Based on those genes, functional profiling was performed with the BioInfoMiner web tool. After the statistical analysis, 63 genes were identified as differentially expressed. The functional profiling revealed interesting terms and pathways, such as mitogen activated protein kinase and cyclic adenosine monophosphate signaling pathways, as well as immune-related mechanisms. A subset of 16 differentially expressed genes from fibroblast gene expression profiling that occurred after Support Vector Machines Recursive Feature Elimination could efficiently separate schizophrenic from healthy controls subjects. These findings suggest that through the analysis of fibroblast based gene expression signature and with the application of machine learning methodologies we might conclude to a diagnostic classification model in schizophrenia.
  Figure/Table
  Supplementary
  Article Metrics

References

1. Kahn RS, Sommer IE, Murray RM, et al. (2015) Schizophrenia. NRDP 1: 15067.

2. Tandon R, Gaebel W, Barch DM, et al. (2013) Definition and description of schizophrenia in the DSM-5. Schizophr Res 150: 3–10.    

3. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-5). Arlington: American Psychiatric Publishing.

4. World Health Organization (2010) International Classification of Diseases, Tenth Revision.

5. Alawieh A, Zaraket FA, Li JL, et al. (2012) Systems biology, bioinformatics, and biomarkers in neuropsychiatry. Front Neurosci 6: 187.

6. Takahashi M, Hayashi H, Watanabe Y, et al. (2010) Diagnostic classification of schizophrenia by neural network analysis of blood–based gene expression signatures. Schizophr Res 119: 210–218.    

7. Yousef M, Najami N, Abedallah L, et al. (2014) Computational approaches for biomarker discovery. JILSA 6: 153–161.    

8. Kotsiantis SB (2007) Supervised Machine Learning: A Review of Classification Techniques. Real Word AI Systems with Applications in eHealth, HCI, Information Retrieval and Pervasive Technologies Emerging Artificial Intelligence Applications in Computer Engineering. Greece: IOS Press. 3–24.

9. Kalman S, Garbett KA, Janka Z, et al. (2016) Human dermal fibroblasts in psychiatry research. Neuroscience 320: 105–121.    

10. Vumma R, Johansson J, Lewander T, et al. (2011) Tryptophan transport in human fibroblast cells-a functional characterization. Int J Tryptophan Res 4: 19–27.

11. Cattane N, Minelli A, Milanesi E, et al. (2015) Altered gene expression in schizophrenia: findings from transcriptional signatures in fibroblasts and blood. Plos One 10: e0116686.    

12. Clelland CL, Read LL, Panek LJ, et al. (2013) Utilization of never-medicated bipolar disorder patients towards development and validation of a peripheral biomarker profile. Plos One 8: e69082.    

13. Dooley EE (2004) National Center for Biotechnology Information. Environ Health Perspect 112: A674.

14. Clough E, Barrett T (2016) The Gene Expression Omnibus Database. Methods Mol Biol 1418: 93–110.    

15. Irizarry RA, Hobbs B, Collin F, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249–264.    

16. Ritchie ME, Phipson B, Wu D, et al. (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43: e47.    

17. Reiner A, Yekutieli D, Benjamini Y (2003) Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19: 368–375.    

18. Koutsandreas T, Pilalis E, Vlachavas EI, et al. (2015) Making sense of the biological complexity through the platform-driven unification of the analytical and visualization tasks. IEEE 15th International Conference on Bioinformatics and Bioengineering (BIBE). Serbia: IEEE Computer Society. 1–6.

19. Croft D, O'Kelly G, Wu G, et al. (2011) Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res 39: D691–697.    

20. Ashburner M, Ball CA, Blake JA, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25–29.

21. Groza T, Kohler S, Moldenhauer D, et al. (2015) The Human Phenotype Ontology: Semantic Unification of Common and Rare Disease. Am J Hum Genet 97: 111–124.    

22. Smith CL, Eppig JT (2012) The Mammalian Phenotype Ontology as a unifying standard for experimental and high-throughput phenotyping data. Mamm Genome 23: 653–668.    

23. Cortes C, Vapnik V (1995) Support-vector networks. Machine Learning 20: 273–297.

24. Dhawan M, Selvaraja S, Duan ZH (2010) Application of committee kNN classifiers for gene expression profile classification. Int J Bioinform Res Appl 6: 344–352.    

25. Díaz-Uriarte R, Alvarez de Andrés S (2006) Gene selection and classification of microarray data using random forest. BMC Bioinformatics 7: 3.    

26. Geurts P, Ernst D, Wehenkel L (2006) Extremely randomized trees. Machine Learning 63: 3–42.    

27. Lou W, Wang X, Chen F, et al. (2014) Sequence Based Prediction of DNA-Binding Proteins Based on Hybrid Feature Selection Using Random Forest and Gaussian Naïve Bayes. Plos One 9: e86703.    

28. Breiman L (2001) Random Forests. Machine Learning 45: 5–32.    

29. Freund Y, Schapire R (1999) A Short Introduction to Boosting. JSAI 14: 771–780.

30. Mozos OM, Stachniss C, Burgard W (2005) Supervised Learning of Places from Range Data using AdaBoost. IEEE International Conference on Robotics and Automation. Spain. 1742–1747.

31. Bergstra J, Bengio Y (2012) Random search for hyper-parameter optimization. J Mach Learn Res 13: 281–305.

32. Pedregosa F, Varoquaux G, Gramfort A, et al. (2011) Scikit-learn: Machine Learning in Python. JMLR 12: 2825–2830.

33. Zhang X, Lu X, Shi Q, et al. (2006) Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics 7: 197.    

34. Barnes MR, Huxley-Jones J, Maycox PR, et al. (2011) Transcription and pathway analysis of the superior temporal cortex and anterior prefrontal cortex in schizophrenia. J Neurosci Res 89: 1218–1227.    

35. Funk AJ, McCullumsmith RE, Haroutunian V, et al. (2012) Abnormal Activity of the MAPK- and cAMP-Associated Signaling Pathways in Frontal Cortical Areas in Postmortem Brain in Schizophrenia. Neuropsychopharmacology 37: 896–905.    

36. Impey S, Obrietan K, Storm DR Making New Connections. Neuron 23: 11–14.

37. Muly C (2002) Signal transduction abnormalities in schizophrenia: the cAMP system. Psychopharmacol Bull 36: 92–105.

38. Xu J, Sun J, Chen J, et al. (2012) RNA-Seq analysis implicates dysregulation of the immune system in schizophrenia. BMC Genomics 13 Suppl 8: S2.

39. Horvath S, Mirnics K (2014) Immune system disturbances in schizophrenia. Biol Psychiatry 75: 316–323.    

40. Toichi M, Kubota Y, Murai T, et al. (1999) The influence of psychotic states on the autonomic nervous system in schizophrenia. Int J Psychophysiol 31: 147–154.    

41. Ward KE, Friedman L, Wise A, et al. (1996) Meta-analysis of brain and cranial size in schizophrenia. Schizophr Res 22: 197–213.    

42. Thompson PM, Stein JL, Medland SE, et al. (2014) The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav 8: 153–182.

43. van Erp TG, Hibar DP, Rasmussen JM, et al. (2016) Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry 21: 585.    

44. Harrison PJ (2004) The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology Berl 174: 151–162.

45. Mahadik SP, Mukherjee S, Laev H, et al. (1991) Abnormal growth of skin fibroblasts from schizophrenic patients. Psychiatry Res 37: 309–320.    

46. Mukherjee S, Mahadik SP, Schnur DB, et al. (1994) Abnormal growth of cultured skin fibroblasts associated with poor premorbid history in schizophrenic patients. Schizophr Res 13: 233–237.    

47. Chan MK, Krebs MO, Cox D, et al. (2015) Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. Transl Psychiatry 5: e601.    

48. Le-Niculescu H, Kurian SM, Yehyawi N, et al. (2008) Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry 14: 156–174.

49. English JA, Fan Y, Focking M, et al. (2015) Reduced protein synthesis in schizophrenia patient-derived olfactory cells. Transl Psychiatry 5: e663.    

50. Ayalew M, Le-Niculescu H, Levey DF, et al. (2012) Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry 17: 887–905.    

51. Iwabuchi SJ, Liddle PF, Palaniyappan L (2013) Clinical Utility of Machine-Learning Approaches in Schizophrenia: Improving Diagnostic Confidence for Translational Neuroimaging. Frontiers in Psychiatry 4: 95.

52. Irani F, Brensinger CM, Richard J, et al. (2012) Computerized Neurocognitive Test Performance in Schizophrenia: A Lifespan Analysis. Am J Geriatr Psychiatry 20: 41–52.

53. Sinn P, Aulmann S, Wirtz R, et al. (2013) Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility. GebFra 73: 932–940.

54. Akin D, Manier DH, Sanders-Bush E, et al. (2004) Decreased Serotonin 5-HT2A Receptor-Stimulated Phosphoinositide Signaling in Fibroblasts from Melancholic Depressed Patients. Neuropsychopharmacology 29: 2081–2087.    

Copyright Info: © 2016, Aristotelis Chatziioannou, et al., licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Article outline

Show full outline
Copyright © AIMS Press All Rights Reserved